Durable Capital Partners, a private equity firm, completed the 110m investment in Abcam, a UK biotechnology company. "Today's equity raise provides greater flexibility to invest in the long term growth of our business to support our customers and capture additional market share through organic and inorganic initiatives," Alan Hirzel, Abcam Chief Executive.